Current Status and Evolution of Immunotherapy in Glioma Management
Jiaying Liu, Guangzhao Yang, Zhengcong Cao, Haozhe Qin, Maorong Zhu, Cheng Zou, Xiao Liu, Yalong He, Jintao Gu · 2026
Read Current Status and Evolution of Immunotherapy in Glioma Management by Jiaying Liu, Guangzhao Yang, Zhengcong Cao, Haozhe Qin, Maorong Zhu, Cheng Zou, Xiao Liu, Yalong He, Jintao Gu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13181368.txt.
Description
Jiaying Liu and co-authors reviewed immune therapy for glioma in a 2026 paper. Gliomas, above all glioblastoma, are the most aggressive primary brain tumours. Surgery cannot remove them fully, the blood-brain barrier blocks drugs, and the tumour setting suppresses immune attack.
The review covers four routes: cancer vaccines, drugs that release immune brakes, cell therapies, and viruses that kill tumour cells. Each has shown promise, with cell therapy strong in early lab work. Barriers remain, including tumour variety, drug delivery, target choice, and immune suppression. The authors back combined treatments and better patient grouping by markers to lift survival.
Catalog record
| CREATOR | Jiaying Liu, Guangzhao Yang, Zhengcong Cao, Haozhe Qin, Maorong Zhu, Cheng Zou, Xiao Liu, Yalong He, Jintao Gu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 127 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |